Stiris Research Inc. Awarded a Pilot Study Using Artificial Intelligence (AI) in Patients with Depression

London, ON — 14 September 2020 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces it has been awarded a Pilot study utilizing artificial intelligence (AI) for clinical diagnosis of Depression.

“Stiris is extremely excited to be working on this first-in-world technology to help treat patients with major depressive disorder. The integration of technology and leveraging advances in artificial intelligence will pave the way for more tailored approach to patient therapy and improve overall care and quality of life,” said Lisa Discepola, Managing Director, Clinical Operations.

​Clinical depression is a complex mood disorder caused by various factors, including genetic predisposition, personality, stress and brain chemistry. Treatments include psychoeducation, psychotherapy, pharmacotherapy, and brain stimulation therapies (electroconvulsive therapy, transcranial magnetic stimulation, and magnetic seizure therapy). Depression can affect anyone: children, adolescents, young adults, middle-aged adults and older people. 20% of adults will have suffered from depression at some point in their lifetimes. Depression may be caused by one factor alone or a combination of factors including biological, psychological and environmental (linked to social or family environment) factors.

( and  (

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.